Track topics on Twitter Track topics that are important to you
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of additional clinical data from the Company’s lead candidate SM-88 being presented in five abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2018 in Chicago, IL.
Details of the poster presentation are as follows:
Title: SM-88 in Advanced Cancers of the Pancreas
Abstract Number: TPS4156
Authors: Marcus Smith Noel, Allyson J. Ocean, Gerald H. Sokol, Steve Hoffman, Giuseppe Del Priore; University of Rochester James P. Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY; Weill Cornell Medical College, New York, NY; Florida Cancer Institute New Hope, Hudson, FL; Tyme Technologies, Inc., New York, NY; Morehouse School of Medicine, Atlanta, GA
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Date/Time: Sunday, June 3rd , 8:00 AM - 11:30 AM CT
Location: Hall A
Additional abstracts are as follows:
Abstract e13100 - SM-88 Efficacy and Safety in Metastatic Breast Cancers
Authors: Xinhua Zhu, Marcus Smith Noel, Patricia Zawisny, Zachary Gostout, Douglas Decorato, Gerald H. Sokol, Maria Loushin, Giuseppe Del Priore; Monter Cancer Center of North Shore - LIJ Health, Lake Success, NY; University of Rochester James P. Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY; QRI, New York, NY; Tyme Technologies, Inc., New York, NY; East River Medical Imaging, NY, NY; Florida Cancer Institute New Hope, Hudson, FL; Quality Research and Invention LLC, New York, NY; Morehouse School of Medicine, Atlanta, GA
Abstract e24072 - Prospective Comparison of Invasive Circulating Tumor Cells (iCTCs) vs PSA and mPFS in Prostate Cancer (PC) Treated with SM-88
Authors: Wen-Tien Chen, Terence W. Friedlander, Huang Dong, Qiang Zhao, Giuseppe Del Priore; Stony Brook University, Stony Brook, NY; University of California San Francisco Medical Center, San Francisco, CA; Vitatex Inc., Stony Brook, NY, US; Tyme Technologies Inc., New York, NY
Abstract e14535 - SM-88 Efficacy Across Multiple High-Risk Factors
Authors: Xinhua Zhu, Marcus Smith Noel, Patricia Zawisny, Zachary Gostout, Douglas Decorato, Maria Loushin, Giuseppe Del Priore; Monter Cancer Center of North Shore - LIJ Health, Lake Success, NY; University of Rochester James P. Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY; QRI, New York, NY; Tyme Technologies, Inc., New York, NY; East River Medical Imaging, NY, NY; Quality Research and Invention LLC, New York, NY; Morehouse School of Medicine, Atlanta, GA
Abstract e14528 - Comparison of SUV and RECIST Responses in Cancers Treated with SM-88
Authors: Dacian V. Bonta, Zachary Gostout, Patricia Zawisny, Maria Loushin, Giuseppe Del Priore; Emory University School of Medicine, Atlanta, GA; Tyme Technologies, Inc., New York, NY; QRI, New York, NY; Quality Research and Invention LLC, New York, NY; Morehouse School of Medicine, Atlanta, GA
The 2018 ASCO Annual Meeting abstracts are currently located on the ASCO Meeting Library.
About Tyme Technologies
Tyme Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
For more information, visit www.tymeinc.com.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88), their clinical potential and non-toxic safety profiles, our drug development plans and strategies, our completed studies, ongoing and planned clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words (including their use in the negative) or by discussions of future matters such as the development of new products, technology enhancements, possible collaborations, the timing, scope and objectives of our planned clinical trials, funding plans and planned uses of proceeds, and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, that the information is of a preliminary nature and may be subject to change; uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase II data may differ from prior study data or preliminary Phase II data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 12, 2017, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission (available at www.sec.gov). The data analyses discussed above are not necessarily predictive of future patient or clinical data outcomes.
The information contained in this press release is as of release date and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...